Abstract:Neurofibromatosis type II (NF2) is a tumor predisposition syndrome characterized by the development of distinctive nervous system lesions. NF2 results from loss-of-function alterations in the <em>NF2</em> gene on chromosome 22, with resultant dysfunction of its protein product merlin. NF2 is most commonly associated with the development of bilateral vestibular schwannomas; however, patients also have a predisposition to development of other tumors including meningiomas, ependymomas, and peripheral, spinal, and cranial nerve schwannomas. Patients may also develop other characteristic manifestations such as ocular lesions, neuropathies, meningioangiomatosis, and glial hamartia. NF2 has a highly variable clinical course, with some patients exhibiting a severe phenotype and development of multiple tumors at an early age, while others may be nearly asymptomatic throughout their lifetime. Despite the high morbidity associated with NF2 in severe cases, management of NF2-associated lesions primarily consists of surgical resection and treatment of symptoms, and there are currently no FDA-approved systemic therapies that address the underlying biology of the syndrome. Refinements to the diagnostic criteria of NF2 have been proposed over time due to increasing understanding of clinical and molecular data. Large-population studies have demonstrated that some features such as the development of gliomas and neurofibromas, currently included as diagnostic criteria, may require further clarification and modification. Meanwhile, burgeoning insights into the molecular biology of NF2 have shed light on the etiology and highly variable severity of the disease and suggested numerous putative molecular targets for therapeutic intervention. Here, we review the clinicopathologic features of NF2, current understanding of the molecular biology of NF2, particularly with regard to central nervous system lesions, ongoing therapeutic studies, and avenues for further research.

Role of Merlin/NF2 inactivation in tumor biology

The NF2 Tumor Suppressor Merlin Interacts with Ras and RasGAP, Which May Modulate Ras Signaling

Merlin Cooperates with Neurofibromin and Spred1 to Suppress the Ras-Erk Pathway.

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity

Merlin regulates signaling events at the nexus of development and cancer

Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated Schwann cell proliferation in human.

Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2

Molecular Insights and Therapeutic Avenues

VprBP Targets Merlin to the Roc1-Cul4A-DDB1 E3 Ligase Complex for Degradation

Combined Mtor/mek Inhibition Prevents Proliferation and Induces Apoptosis in NF2-mutant Tumors

Molecular Alterations of the NF2 Gene in Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Current progress in genomics and targeted therapies for neurofibromatosis type 2

Tumorigenic Transformation by CPI-17 Through Inhibition of a Merlin Phosphatase.

The Tumor Suppressor Merlin Is Required For Cell Cycle Exit, Terminal Differentiation, And Cell Polarity In The Developing Murine Lens

Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

The genetic landscape and possible therapeutics of neurofibromatosis type 2

An update on the CNS manifestations of neurofibromatosis type 2

The Phosphorylation Status of Merlin in Sporadic Vestibular Schwannomas.

A Novel NF2 Mutation Associated with Neurofibromatosis Type 2 Causes Aberrant Splicing and Phase Separation

Gatekeeping role of Nf2 /Merlin in vascular tip EC induction through suppression of VEGFR2 internalization